EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 8-9 (Août-Septembre 2009) Med Sci (Paris), 25 8-9 (2009) 661-663 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 8-9, Août-Septembre 2009
Page(s) 661 - 663
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2009258-9661
Published online 15 August 2009
  1. OMS. Global tuberculosis control : epidemiology, strategy, financing. WHO Report. Geneva : WHO, 2009. [Google Scholar]
  2. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004; 84 : 29–44. [Google Scholar]
  3. Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009; 9 : 19–30. [Google Scholar]
  4. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368 : 1575–80. [Google Scholar]
  5. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929; 10 : 226–36. [Google Scholar]
  6. Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 2007; 46 : 11998–2004. [Google Scholar]
  7. Tremblay LW, Hugonnet JE, Blanchard JS. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate. Biochemistry 2008; 47 : 5312–6. [Google Scholar]
  8. Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea : risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008;46 : 42–9. [Google Scholar]
  9. Hugonnet JE, Tremblay LW, Boshoff HI, et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323 : 1215–8. [Google Scholar]
  10. Wayne, LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64 : 2062–9. [Google Scholar]
  11. Lavollay M, Arthur M, Fourgeaud M, et al. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. J Bacteriol 2008; 190 : 4360–6. [Google Scholar]
  12. Mainardi JL, Fourgeaud M, Hugonnet JE, et al.A novel peptidoglycan cross-linking enzyme for a beta-lactam-resistant transpeptidation pathway. J Biol Chem 2005; 280 : 38146–52. [Google Scholar]
  13. Saint-Joanis B, Brosch R. Découverte d’une nouvelle classe très prometteuse d’antituberculeux : les benzothiazinones (BTZ). Med Sci (Paris) 2009;25 : 663–5. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.